Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

372 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Targeted deep sequencing improves outcome stratification in chronic myelomonocytic leukemia with low risk cytogenetic features.
Palomo L, Garcia O, Arnan M, Xicoy B, Fuster F, Cabezón M, Coll R, Ademà V, Grau J, Jiménez MJ, Pomares H, Marcé S, Mallo M, Millá F, Alonso E, Sureda A, Gallardo D, Feliu E, Ribera JM, Solé F, Zamora L. Palomo L, et al. Among authors: feliu e. Oncotarget. 2016 Aug 30;7(35):57021-57035. doi: 10.18632/oncotarget.10937. Oncotarget. 2016. PMID: 27486981 Free PMC article.
Impact of mutational studies on the diagnosis and the outcome of high-risk myelodysplastic syndromes and secondary acute myeloid leukemia patients treated with 5-azacytidine.
Cabezón M, Bargay J, Xicoy B, García O, Borrás J, Tormo M, Marcé S, Pedro C, Valcárcel D, Jiménez MJ, Guàrdia R, Palomo L, Brunet S, Vall-Llovera F, Garcia A, Feliu E, Zamora L; CETLAM Group. Cabezón M, et al. Among authors: feliu e. Oncotarget. 2018 Apr 10;9(27):19342-19355. doi: 10.18632/oncotarget.25046. eCollection 2018 Apr 10. Oncotarget. 2018. PMID: 29721207 Free PMC article.
Diagnostic and prognostic contribution of targeted NGS in patients with triple-negative myeloproliferative neoplasms.
Acha P, Xandri M, Fuster-Tormo F, Palomo L, Xicoy B, Cabezón M, Marcé S, Granada I, Vela D, Sagüés M, Boque C, Plensa E, Pineda A, Feliu E, Solé F, Zamora L. Acha P, et al. Among authors: feliu e. Am J Hematol. 2019 Oct;94(10):E264-E267. doi: 10.1002/ajh.25580. Epub 2019 Aug 6. Am J Hematol. 2019. PMID: 31321810 Free article. No abstract available.
Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.
Marcé S, Zamora L, Cabezón M, Xicoy B, Boqué C, Fernández C, Grau J, Navarro JT, Fernández de Sevilla A, Ribera JM, Feliu E, Millá F; Grupo ICO de estudio de mutaciones de ABL en pacientes afectos de LMC. Marcé S, et al. Among authors: feliu e. Med Clin (Barc). 2013 Aug 4;141(3):95-9. doi: 10.1016/j.medcli.2012.10.028. Epub 2013 Feb 22. Med Clin (Barc). 2013. PMID: 23433665
Co-existence of JAK2 V617F and CALR mutations in primary myelofibrosis.
Zamora L, Xicoy B, Cabezón M, Fernandez C, Marcé S, Velez P, Xandri M, Gallardo D, Millá F, Feliu E, Boqué C. Zamora L, et al. Among authors: feliu e. Leuk Lymphoma. 2015;56(10):2973-4. doi: 10.3109/10428194.2015.1015124. Epub 2015 Mar 11. Leuk Lymphoma. 2015. PMID: 25686645 No abstract available.
Highly variable mutational profile of ASXL1 in myelofibrosis.
Sorigué M, Ribera JM, García O, Cabezón M, Vélez P, Marcé S, Xicoy B, Fernández C, Buch J, Cortes M, Plensa E, Gallardo D, Boqué C, Feliu E, Zamora L. Sorigué M, et al. Among authors: feliu e. Eur J Haematol. 2016 Oct;97(4):331-5. doi: 10.1111/ejh.12731. Epub 2016 Jan 19. Eur J Haematol. 2016. PMID: 26714837
372 results